Physician profile
Sudhakar Tumuluri
NPI 1639181670
$2,771,283.70
in general payments reported to CMS, 2019-2025
32 companies · $501K in 2025
The $501K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281K · 2020: $173K · 2021: $300K · 2022: $435K · 2023: $555K · 2024: $528K · 2025: $501K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Travel and Lodging: $365K · Honoraria: $126K · Consulting Fee: $39K · Food and Beverage: $38K · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,014,979.66 |
| Travel and Lodging | $365,154.87 |
| Honoraria | $126,225.00 |
| Consulting Fee | $38,504.00 |
| Food and Beverage | $38,169.44 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $550,638.82 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $497,410.23 | 2019-2025 | Taltz, Olumiant |
| Janssen Biotech, INC. | $323,712.97 | 2019-2025 | Simponi Aria, Tremfya, Simponi |
| Janssen Scientific Affairs, LLC | $318,440.09 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $241,978.09 | 2019-2025 | Uplizna, Otezla, Tavneos |
| Ani Pharmaceuticals, INC. | $190,993.10 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $188,841.25 | 2020-2025 | Acthar |
| Genzyme Corporation | $171,378.11 | 2019-2025 | |
| Ucb, INC. | $88,333.86 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80,648.40 | 2020-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $54,289.99 | 2019-2025 | |
| Celgene Corporation | $35,605.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16,548.58 | 2019 | |
| Horizon Therapeutics Plc | $3,017.08 | 2019-2023 | Krystexxa |
| Pfizer INC. | $3,014.65 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,177.22 | 2019-2020 | |
| Abbvie INC. | $1,351.02 | 2019-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $639.76 | 2019-2023 | Nucala |
| E.R. Squibb & Sons, L.L.C. | $355.44 | 2019-2024 | Orencia |
| Sanofi-Aventis U.S. LLC | $320.75 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $315.61 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $251.56 | 2023 | Idacio |
| Aurinia Pharma U.S., INC. | $251.26 | 2022-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $210.19 | 2019 | |
| Genentech, INC. | $146.98 | 2025 | Gazyva |
| Radius Health, INC. | $130.06 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $108.91 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $90.38 | 2019-2022 | |
| Hologic Sales and Service, LLC | $27.89 | 2019 | |
| Octapharma USA, INC. | $23.76 | 2024 | Cutaquig |
| Scilex Pharmaceuticals INC. | $22.78 | 2025 | |
| Eli Lilly and Company | $9.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhakar Tumuluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.